Affiliation:
1. Institut za reumatologiju, Beograd
2. nema
Abstract
Introduction. Osteoporosis is a major health and economic problem worldwide.
The use of new drugs, such as ibandronate, is aimed at improving treatment of
osteoporosis and currently poor compliance with BP therapy. Objective. To
investigate efficacy and safety of ibandronate applied monthly, orally, in
women with low bone mineral density (BMD). Methods. The prospective study was
conducted in 34 centers in Serbia and included 77 women treated for 24 months
with monthly ibandronate. The efficacy of treatment was assessed by change in
bone mass values obtained by BMD measurement at the end of 24 months
follow-up versus baseline and 12-months follow-up values. Compliance and
safety, i.e. adverse effects (AE) were recorded. Results. Participants were
postmenopausal (96%), osteoporotic (79.7%) females, diagnosed by lumbar spine
DXA measurement (81%), with history of prior BP therapy in 33.8% women. The
physical activity level significantly increased to the substantial level of
activity (5.2% vs. 21.3%, p=0.003) during the study. After 12 and 24 months
of treatment, BMD values significantly increased (p=0.002 and p<0.001). BP
experienced patients improved more than BP na?ve patients at both time points
(p=0.012 and p=0.027, respectively). During the second 12 months of treatment
the adherence was 96%; AE were recorded as mild gastrointestinal disturbances
in 3.9%. Conclusion. Treatment by using ibandronate once monthly for 24
months was generally well tolerated and led to a significant increase in BMD
in women with low BMD.
Publisher
National Library of Serbia
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献